Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data

Company Posts Solid Q2 Sales Despite REGEN-COV Drop

Executive Summary

The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.

You may also be interested in...



Libtayo Gains Approval for First-Line NSCLC With Chemotherapy

Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.

Regeneron Gets Encouraging Early Data For Bispecifics In Solid Tumors

The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.

As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064

Vopratelimab is the second major ICOS agonist program to fail since GSK halted studies of feladilimab last year, but an analyst pinned higher hopes on JTX-8064.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel